404
Participants
Start Date
April 8, 2025
Primary Completion Date
October 15, 2026
Study Completion Date
April 15, 2027
Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib
The backbone is chemotherapy which will be used in the control group. The precision group will add targeted therapy agents which were determined according to SNF classification: the SNF2 subtype add adebrelimab combined with famitinib, the SNF3 subtype receives fluzoparib, and the SNF4 subtype receives apatinib.
Chemotherapy (wP-EC)
Chemotherapy : weely nab-P \* 12- EC \* 4
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER